immunoglobulins called IgA, for certain patients experiencing adverse
reactions from other IGIV therapies.
-- GAMMAGARD LIQUID and GAMMAGARD S/D Portability - Launched in late 2006,
this program is designed to provide hospitals with continued access to
GAMMAGARD irrespective of changes to their group purchasing
Patient organizations welcomed the announcement of Baxter's newest patient access innovation. "Access to the IGIV product prescribed by their physician is extremely important for PI patients," said Marcia Boyle, founder and president of the Immune Deficiency Foundation, a national nonprofit patient organization dedicated to improving the diagnosis and treatment of primary immunodeficiency diseases through research, education and advocacy. "Baxter's program will be extremely helpful to PI patients by reassuring that they will not have to change from their product of choice." Noting the success of Baxter's other patient centric initiatives, Ms. Boyle added, "We would love to see such a program developed for all of the patients in our community who use GAMMAGARD LIQUID and GAMMAGARD S/D."
"Baxter has been a pioneer in advancing the science of IGIV, and its intent to establish a program that maintains continuity in IGIV therapy at the patient level is an important innovation in the industry -- one that is sure to be embraced by PID patients who use GAMMAGARD LIQUID and GAMMAGARD S/D," added Fred Modell, co-founder of the Jeffrey Modell Foundation, a national nonprofit organization dedicated to early and precise diagnosis, meaningful treatment and ultimately cures of PID.
Baxter's GARDian Program
Baxter plans to launch a pilot of GARDian in early 2008. The pilot
initiative and the ensuing program will be open to current patients in the
United States that routinely use the product as prescribed by a physician.
Using a simple, volunt
|SOURCE Baxter International Inc.|
Copyright©2007 PR Newswire.
All rights reserved